BHQ880

anti-DKK1 monoclonal antibody · Novartis Pharmaceuticals

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for BHQ880, covering 2013-02-18 to 2020-12-17. Get the full timeline:

Most recent: Clinical Trial Update: Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma [Phase 2]